BrainsWay Ltd. ADR (BWAY)
NASDAQ: BWAYHealth CareMedical/Dental InstrumentsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
BWAY stock chart
Technical analysisKey statistics
All statistics- Market cap
- $341.35M
- P/E (TTM)
- 35.33
- Forward P/E
- 16.96
- EPS (TTM)
- $0.24
- Dividend yield
- None
- 52-week range
- 7.30 – 17.40
- Day range
- 8.45 – 8.96
- Volume / Avg
- 109.52K / 110.35K
- Beta
- —
- Shares outstanding
- 40.25M
52-week range
BWAY stock today
Shares of BrainsWay (BWAY) finished lower on Nov 20 at $8.48, a drop of 2.86% or $0.25 per share, versus the S&P 500's 3.70% decline. Shares are 51.3% below their 52-week high of $17.40, set on Aug 12, 2026 and 16.2% above the 52-week low of $7.30, near the bottom of the past year's range. BWAY is down 10.8% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 13.9%.
At 35.3x trailing earnings, BrainsWay trades above the peer-group median of 18.0x. Its forward P/E of 17.0x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.
Summary generated from market data by MetaCap's automated system. Methodology
About BrainsWay
Company profileBrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious and late-life depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- CEO
- Mr. Hadar Levy
- Headquarters
- Jerusalem
- Employees
- 129
- IPO year
- 2019
- Website
- brainsway.com
Financial highlights
Full financialsIn fiscal 2024, BrainsWay generated $41.0 million in revenue, up 29.0% from fiscal 2023, its 2nd consecutive year of revenue growth. Net income was $2.9 million, for a net margin of 7.1% versus a median of -24.4% in the prior 5 years. Gross margin was 74.6% (up from 73.9%) and operating margin 3.4%.
| Fiscal year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Revenue | $41.02M | $31.79M | $27.18M | $29.66M | $22.06M |
| Growth | +29.04% | +16.96% | -8.36% | +34.46% | -4.52% |
| Net income | $2.92M | $-4.20M | $-13.35M | $-6.46M | $-5.38M |
| EPS (diluted) | $0.05 | $-0.13 | $-0.40 | $-0.21 | — |
Analyst forecast
ForecastConsensus (3 analysts)
strong_buy
Avg. price target
$19.27+127.24%
- Strong buy 0
- Buy 3
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 10, 2026
- EPS actual vs est.
- $0.04 vs $0.12
- Surprise
- -66.67%
BWAY news
All BWAY news- BrainsWay: 3 Key Takeaways for Long-Term InvestorsNasdaq
- BrainsWay (BWAY) Q3 2026 Earnings Call TranscriptNasdaq
- BrainsWay Reports Third Quarter 2026 Financial Results and Operational HighlightsGlobeNewswire
- BrainsWay Announces Strategic Collaboration with Mindful Health SolutionsGlobeNewswire
- BrainsWay to Report Third Quarter 2026 Financial Results on November 10, 2026GlobeNewswire
- BrainsWay Ltd. Amends Notice of Annual General Meeting Scheduled for November 25, 2026Nasdaq
- BrainsWay Expands U.S. Insurance Coverage for Deep TMS™ Treatment of OCD to Over 118 Million LivesGlobeNewswire
- BrainsWay - Depositary Receipt Price Target Increased by 218.89% to $0.20Nasdaq
BrainsWay peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| EMBCEmbecta Corp. | 6.02 | -2.75% | $341.09M | vs BWAY |
| CERSCerus Corporation | 1.85 | -2.63% | $373.62M | vs BWAY |
| MOBIMobia Medical Inc. | 11.85 | -0.08% | $394.50M | vs BWAY |
| INFUInfuSystems Holdings Inc. | 14.35 | +2.06% | $287.48M | vs BWAY |
| TMCITreace Medical Concepts Inc. | 4.31 | -0.92% | $282.56M | vs BWAY |
| NPCENeuropace Inc. | 7.95 | -2.33% | $273.89M | vs BWAY |
| SIShoulder Innovations Inc. | 20.15 | -0.79% | $421.58M | vs BWAY |
| SSIISS Innovations International Inc. | 1.27 | -0.78% | $254.86M | vs BWAY |
Indexes, lists and sector
BrainsWay stock FAQ
What is BrainsWay's stock price today?
BWAY last traded at $8.48 as of Nov 20, 4:00 PM EST, down 2.86% on the day. Prices are delayed at least 15 minutes.
Does BrainsWay pay a dividend?
No. BrainsWay does not currently pay a regular cash dividend.
What is BWAY's P/E ratio?
BWAY trades at a trailing P/E ratio of 35.33 and a forward P/E of 16.96, compared with a median of 18.0 for its closest peers.
Who is BrainsWay's CEO?
Mr. Hadar Levy is the chief executive officer of BrainsWay Ltd. ADR, which has about 129 employees.
Has BWAY ever split its stock?
Yes. The most recent BWAY stock split was a 2-for-1 split on Mar 4, 2026.
What is the BWAY 52-week high?
The 52-week high for BWAY is $17.40 and the 52-week low is $7.30. The stock is currently 51.3% below its high.